Market Overview

Interpace Diagnostics Partners With AI Specialist To Diagnose Thyroid Cancer


Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced it completed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), which is focused on applying artificial intelligence to personalized medicine and drug discovery.

It's estimated that the treatment market for thyroid cancer was valued at approximately $340 million in 2018 and is expected to reach $2.1 billion by the end of 2025.

Under the agreement, the companies will develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations.

“The better we understand thyroid cancer, the better equipped we are to both diagnose and predict treatment outcomes,” said Jack Stover, CEO of Interpace Diagnostics. “We believe that this collaboration with Helomics is a significant step to help us better diagnose thyroid cancer, resulting in existing product line extensions as well as potentially new products and partnerships based on the AI-driven models Helomics is building."

Related Links:

Cancer Genetics Sharply Higher After Interpace Buys Biopharma Unit

14 Stocks To Watch For July 18, 2019

Posted-In: News Penny Stocks Health Care Contracts Markets General


Related Articles (IDXG + POAI)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mnuchin Says Markets Shouldn't Be 'Concerned' With Debt Ceiling

In Rare Move, Schwab Expected To Launch New ETFs